Chen-Hua Liu
Overview
Explore the profile of Chen-Hua Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
2140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
3.
Chang Y, Lee J, Chen C, Kao W, Lin C, Yang S, et al.
Aliment Pharmacol Ther
. 2025 Feb;
PMID: 39981689
Background: Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct-acting antivirals (DAAs)-induced sustained virologic response (SVR) remains limited....
4.
5.
Chang Y, Huang C, Kao J, Su T, Huang S, Tseng T, et al.
J Formos Med Assoc
. 2025 Jan;
PMID: 39848863
Background: Limited data exists regarding the long-term serum ferritin dynamics following sustained virologic response (SVR) and factors associated with trends in changes among patients undergoing treatment for hepatitis C virus...
6.
Chang K, Su T, Wu C, Huang S, Tseng T, Hong C, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39777761
Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), defined by steatotic liver disease (SLD) and cardiometabolic factors, is increasing in prevalence, but its association with heart failure (HF) is unclear. Methods...
7.
Huang S, Su T, Tseng T, Hsu S, Hong C, Lan T, et al.
J Hepatol
. 2024 Dec;
PMID: 39675434
Background & Aims: Steatotic liver disease (SLD) is prevalent among patients with chronic hepatitis B (CHB). However, the effects of metabolic dysfunction-associated SLD (MASLD) on the long-term survival of such...
8.
Hong C, Su T, Hsu S, Tseng T, Liu C, Yang H, et al.
J Formos Med Assoc
. 2024 Nov;
PMID: 39488497
Background And Aims: Direct-acting antiviral agents (DAAs) achieve high sustained virologic response (SVR) in chronic hepatitis C patients; yet a proportion of patients still experience de novo liver complications after...
9.
Liu C, Cheng P, Fang Y, Chen C, Kao W, Lin C, et al.
J Hepatol
. 2024 Oct;
PMID: 39368711
Background & Aims: Data are limited on the risk of de novo hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) after achieving sustained virologic response at...
10.
Tsai F, Su T, Huang S, Tseng T, Hsu S, Liao S, et al.
Cancer
. 2024 Sep;
131(1):e35541.
PMID: 39238423
Background: Steatotic liver disease (SLD) is an emerging liver disease that has been associated with an increased risk for hepatocellular carcinoma (HCC). The impact of concurrent SLD on the prognosis...